UMich taps MDxHealth diagnostic for new cancer risk clinic
IRVINE, Calif. & HERSTAL, Belgium—MDxHealth SA reported in Q1 that its SelectMDx for Prostate Cancer—a non-invasive, urine-based test that guides patient selection for prostate biopsy—was selected for the University of Michigan’s new prostate cancer risk clinic. The Michigan Medicine clinic will monitor men who were previously diagnosed with genetic mutations that indicate a genetic predisposition to developing aggressive prostate cancer. High-risk patients will be tested with SelectMDx for Prostate Cancer to determine the likelihood that clinically significant prostate cancer would be detected in a biopsy. The test can aid oncologists in differentiating between men with a high likelihood of cancer upon biopsy and the probability for high-grade disease, from men at very low risk of aggressive disease, with a 98-percent negative predictive value.